

INFORME DE BÚSQUEDA DE PATENTES

N° de solicitud: NC2016/0003933

CRITERIOS PARA LA BÚSQUEDA (Anexar pantallazo o reporte en PDF, junto con los boléanos utilizados*. Para el caso de secuencias, anexar alineamientos)

PALABRAS CLAVE UTILIZADAS (Pirlindole OR pyrazidol) AND tablet* AND lactos*

CLASIFICACIONES UTILIZADAS PARA LA BÚSQUEDA
CIP: A61K31/4985; A61P25/04
CPC: A61K31/4985; A61K45/06; A61K47/02; A61K9/0019; A61K9/2018; A61K31/4985, A61K2300/00

DOCUMENTOS CONSIDERADOS RELEVANTES (documentos patentes, literatura no patente, etc...)

Informes/Base de datos	N° de solicitud/ Autor**	Fecha de Publicación/Presentación (DD/MM/AAAA)	Reiv. afectadas (Con indicación, si procede, de las partes relevantes o números de secuencias)	Categorías especiales de los documentos citados***
SIPI (Obligatoria)	----	----	----	----
USPTO	US5397796	14/03/1995	1	Y
Google Patents	EP1301140	30/11/2005	1	Y
	WO2010/068867	17/06/2010	1	Y
	WO2015/171002	12/11/2015	----	E
	EP1688161	09/08/2006	----	A
EPOQUE NET*	RU2002122482	10/03/2004	----	A
STN	GB1340528	12/12/1973	1	Y
	RU2223752	20/02/2004	----	A
Espacenet	US2004106681	03/06/2004	1	Y
	EP1300140	09/04/2003	1	Y

*** Categorías especiales de documentos citados:

“A” documento que define el estado general de la técnica no considerado como particularmente relevante.
 “E” solicitud de patente o patente anterior pero publicada en la fecha de presentación internacional o en fecha posterior.
 “P” documento publicado antes de la fecha de presentación internacional pero con posterioridad a la fecha de prioridad reivindicada.
 “X” documento particularmente relevante; la invención reivindicada no puede considerarse nueva o que implique una actividad inventiva por referencia al documento aisladamente considerado.
 “Y” documento particularmente relevante; la invención reivindicada no puede considerarse que implique una actividad inventiva cuando el documento se asocia a otro u otros documentos de la misma naturaleza, cuya combinación resulta evidente para un experto en la materia.

**** Indicar entre paréntesis la Autoridad que realizó la búsqueda o el informe preliminar Ejs: EPO, JP, INAPI.

Literatura no patente

**Se incluye entre otros, toda la referencia de la literatura no patente.

Tullio, P., Ceccato, A., Liégeois, J. F., Pirotte, B., Felikidis, A., Stachow, M., Hubert, P., Crommen, J., Geczy J. and Delarge, J. Effective resolution of racemic pirlindole at the preparative scale. Chirality, 1999, 11, 261-266.

Rowe, R. C., Sheskey, P. J. and Quinn, M. Handbook of Pharmaceutical Excipients. 6 Ed. Pharmaceutical Press. 2009. Pág. 129-133, 185-188, 206-208, 326-329, 364-369, 404-407.

Hauser, W., Bernardy, K., Uceyler, N. and Sommer, C. Treatment of Fibromyalgia Syndrome with Antidepressants A Meta-analysis. JAMA. 2009, 301, 2, 198-209.

Fecha del reporte de búsqueda:

27/10/2018

3111191

TECNIMEDE SOCIEDADE TECNICO-MEDICINAL S.A.

Suprimir

789456

TECNIMEDE SOCIEDADE TECNICO-MEDICINAL S.A.

Suprimir

TECNIMEDE-SOCIEDADE TÉCNICO-MEDICINAL, S.A.

Suprimir

TECNIMEDE-SOCIEDADE TECNICO-MEDICINAL, S.A.

Suprimir

Mostrar / Ocultar columnas

Buscar

Examinador Principal

Seleccionar

Con/Sin Oposición

Número de Resolución

Buscar

Limpiar

7 Casos asociados

Número de solicitud	Tipo de solicitud	Título/Denominación	Etiqueta	Fecha de radicación	Estado(s)	Examinador Principal	Titular
☐ 15141733	Patente PCT	QUINOLIL HIDRAZONAS PARA EL TRATAMIENTO DE LA TUBERCULOSIS Y ENFERMEDADES RELACIONADAS		19 jun 2015	Negada	EMILCE CANO URREGO	TECNIMEDE SOCIEDADE TECNICO-MEDICINAL S.A.
☐ 15141735	Patente PCT	PIRIDIL HIDRAZONAS QUE COMPRENDEN 2-TIENIL SUSTITUIDO		19 jun 2015	Concedido	NELSON RICARDO VELASCO GONZALEZ	TECNIMEDE SOCIEDADE TECNICO-MEDICINAL S.A.
☐ 15297433	Patente PCT	COMPOSICIÓN SÓLIDA QUE COMPRENDE ÁCIDO IBANDRÓNICO O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO, VITAMINA D Y UN TRIGLICÉRIDO DE CADENA MEDIA O UN ACEITE VEGETAL HIDROGENADO		16 dic 2015	Requerimiento de Examen de Fondo	GERMAN ANTONIO CLAVIJO COHEN	TECNIMEDE SOCIEDADE TECNICO-MEDICINAL S.A.
☐ NC2015/0003524	Patente PCT	(S)-PIRLINDOLE MESILATO Y (R)-PIRLINDOLE MESILATO, COMPOSICIONES QUE LAS COMPRENDEN Y MÉTODOS PARA SU ELABORACIÓN		09 nov 2016	Bajo Examen de Fondo	Katherine Manrique Perico	TECNIMEDE SOCIEDADE TECNICO-MEDICINAL S.A.
☐ NC2015/0003526	Patente PCT	PROCESO DE OBTENCIÓN DE ENANTIOMEROS DE PIRLINDOLE Y PREPARACIÓN DE SALES S)-MANDELATO, BROMHIDRATO, CITRATO, MESILATO Y (R)-(+)-D-METOXI-D-TRIFLUOROFENIL ACETATO		09 nov 2016	Bajo Examen de Fondo	NELSON RICARDO VELASCO GONZALEZ	TECNIMEDE SOCIEDADE TECNICO-MEDICINAL S.A.
☐ NC2015/0003529	Patente PCT	COMPOSICIONES SOLIDAS DE SAL DE CLORHIDRATO DE R-PIRLINDOLE		09 nov 2016	Bajo Examen de Fondo	Katherine Manrique Perico	TECNIMEDE SOCIEDADE TECNICO-MEDICINAL S.A.
☐ NC2015/0003933	Patente PCT	COMPOSICIONES DE (S)-PIRLINDOLE Y SUS SALES FARMACÉUTICAMENTE ACEPTABLES		09 nov 2016	Bajo Examen de Fondo	LEONARDO FERNANDEZ RODRIGUEZ	TECNIMEDE SOCIEDADE TECNICO-MEDICINAL S.A.

Google Patents

(((pirindole) OR (pyrazidol) OR (pirindol))) (lactose) (tablet)

Sign In

SEARCH TERMS

(((pirindole) OR (pyrazidol) OR (pirindol)))

or + Synonym

lactose

x or + Synonym

tablet

x or + Synonym

+ Synonym

SEARCH FIELDS

Date - Priority

YYYY-MM-DD - YYYY-MM-DD

Inventor

Assignee

Patent Office - Language

Status - Type

About 912 results

Sort by - Relevance - Grouped by - None - Results / page - 10 -

Long release matricial formulations of pirlindol hydrochloride

DE EP ES - Grant EP130014081 - Sousa Goucha Jorge Pedro Manuel De - Tecnimed-Sociedade Tecnico-Medicinal, S.A. Priority 2001-10-08 - Filing 2001-10-08 - Grant 2005-11-30 - Publication 2005-11-30 Sodium alginate 74.00 Polymer for prolonging the release Cellactose® (lactose monohydrate + microcrystalline cellulose 710.80 Diluent Magnesium ... according to claim 1, characterized in that the pharmaceutical forms obtained are tablets or grains, for example pellets, for oral administration.

Methods for treating multiple sclerosis using tetracyclic pyrazinoidoles

CA CN EP JP US WO - Application WO2010068867A1 - Spyros Dettreos - Biovista, Inc. Priority 2008-12-11 - Filing 2009-12-11 - Publication 2010-06-17 Methods and pharmaceutical compositions for treating multiple sclerosis are described. The methods and pharmaceutical compositions include a therapeutically effective amount of one or more tetracyclic pyrazinoidoles, and/or pharmaceutically acceptable salts thereof.

Administration of phosphodiesterase inhibitors for the treatment of premature ...

CA EP JP US WO - Grant US6403597B1 - Leland F. Wilson - Vivus, Inc. Priority 1997-10-28 - Filing 2001-06-21 - Grant 2002-06-11 - Publication 2002-06-11 A method is provided for treatment of premature ejaculation by administration of a phosphodiesterase inhibitor, e.g., an inhibitor of a Type III, Type IV, or Type V phosphodiesterase. In a preferred embodiment, administration is on as "as needed" basis, i.e., the drug is administered immediately ...

Tablet for instant and prolonged release of one or more active substances

CA CN DE DK EP ES FR JP RU US WO - Grant US6972255B1 - Olivier Saslawski - Merck Patent Gesellschaft Priority 1997-12-23 - Filing 1998-12-11 - Grant 2002-04-16 - Publication 2002-04-16 Fine lactose powder 17.20% Eudragit NE 30 D 8.80% Talc 1.10% Magnesium Stearate 1.20% Total 100.00% The active ingredient and the lactose are ... 6. A tablet according to claim 1, wherein the first layer further comprises one or more disintegrating agents. 7. A tablet according to claim 1,

Modified release multiple-units compositions of non-steroid anti-inflammatory ...

CA CN DE EP JP US WO - Grant US6595529B1 - Annette Skinhøj - Nycomed Danmark A/S Priority 1997-09-11 - Filing 1998-09-10 - Grant 2003-07-29 - Publication 2003-07-29 An oral pharmaceutical modified release multiple-units composition for the administration of a therapeutically and/or prophylactically effective amount of a non-steroid anti-inflammatory drug substance to obtain both a relatively fast onset of the therapeutic effect and the maintenance of a ...

On demand administration of clomipramine and salts thereof to treat premature ...

CA EP US WO - Grant US6495154B1 - Peter Tam - Vivus Inc. Priority 2000-11-21 - Filing 2000-11-21 - Grant 2002-12-17 - Publication 2002-12-17 A method is provided for delaying the onset of ejaculation in an individual. The method involves systemic and on demand administration of a therapeutically effective amount of clomipramine and salts thereof to an individual.

Top 1000 results by filing date



Relative count of top 5 values

Assignees	Inventors	CPCs
Schering Corporation A61K31/397 A61K31/7042 A61K31/70 A61K31/7052		8.2%
Emory University A61K31/517 A61K31/496 C07H19/02 C07H19		4.4%
Zafgen Corporation C07D493/00 C07D493 C07D493/02 C07D		3.4%
Collegium Pharmaceutical, Inc. A61K9/284 A61K9/2846 A61K9/2833 A61K9/2806		3.1%
Synergy Pharmaceuticals Inc. C07K7/08 C07K7/04 C07K7/00 C07K7		2.4%

Expand

Internal - Current DB: EPODOC - Search Recording ON

File Edit PDB X-File Options Help

Results in EPODOC 14,455

[SS 6] 1 and 2

Results in EPODOC 2

[SS 7] ..II

1/2 EPODOC / EPO

PN - UA53205 C2 20060615

PR - UA20020042656 20020403

AP - UA20020042656 20020403

DT - I

PA - PHARMATECH CLOSE JOINT STOCK C [UA]

TI - ANTIDEPRESSANT FORMULATION AND METHOD FOR ITS MANUFACTURE

AB - The antidepressant formulation contains indole derivative and the excipients at a 1.00:(2.25-3.95) ratio. **Pyrazidol**, tetrindol or incasan are used as indole derivative. The following excipients are employed: starch, or cellulose, or the derivatives of thereof; stearic acid of stearates; the sugar, or **lactose**, or derivatives of thereof. The method for manufacturing of the formulation provides for mixing **pyrazidol**, tetrindol or incasan with the excipients stated above and processing the mixture to the ready-for-use dosage form.

2/2 EPODOC / EPO

PN - RU2002122482 A 20040310

PNFP - RU2223752 C1 20040220

PR - UA20020042656 20020403

AP - RU20020122482 20020819

DT - I

TI - (C1) PHARMACEUTICAL COMPOSITION ELICITING ANTIDEPRESSANT EFFECT AND METHOD FOR IT PREPARING

AB - (C1) FIELD: medicine, pharmacy. SUBSTANCE: invention relates to pharmaceutical composition eliciting antidepressant effect and method for it preparing. Pharmaceutical composition comprises indole derivative and special additions. As an indole derivative pharmaceutical composition comprises **pyrazidol** or incazan, or tetrindol. Special additions are taken among the following groups: group including starch, cellulose or its derivative; group including stearic acid, stearates; group including sugar, **lactose** or its derivative taken in the definite ratio of components. Pharmaceutical composition represents solid medicinal form. Also, invention

File: Internal Mode: Insert

Help F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 Break >>>

History - Internal

Database	SS	Status	Results	Query
EPODOC	1		77 PIRLINDOLE OR PYRAZIDOL	
	2		13718 LACTOSE	
	3		2 1 AND 2	
	4		0 LACTOS*	
	5		14455 LACTOS*	
	6		2 1 AND 2	

☒ Keep dialog open ☐ Current Database ☐ Show metadata ☐ Expand rows (Cluster DBs)

☐ All Databases

Save as preparation Rank and View Send to Viewer Save as XFile Close Help

☐ Add to Current WL

STNnext Report


Title: NC20160003933

Date of search: 10/27/2018


Database info: CAPLUS, REGISTRY

L2 3 ANSWERS REGISTRY COPYRIGHT 2018 ACS on STN
 IN 1H-Pyrazino[3,2,1-jk]carbazole, 2,3,3a,4,5,6-hexahydro-8-methyl-, (3aR)-, methanesulfonate (1:1)
 CM 1

Absolute stereochemistry.




CM 2




L2 3 ANSWERS REGISTRY COPYRIGHT 2018 ACS on STN
 IN Benzeneacetic acid, α -methoxy- α -(trifluoromethyl)-,
 (α R)-, compd. with (3aR)-(3aR)-2,3,3a,4,5,6-hexahydro-8-methyl-1H-
 pyrazino[3,2,1-jk]carbazole (1:1)
 CM 1

Absolute stereochemistry.




CM 2

Absolute stereochemistry. Rotation (+).



L2 3 ANSWERS REGISTRY COPYRIGHT 2018 ACS on STN
 IN 1H-Pyrazino[3,2,1-jk]carbazole, 2,3,3a,4,5,6-hexahydro-8-methyl-,
 conjugate acid (1:1)




• H⁺

ALL ANSWERS HAVE BEEN SCANNED


L3 34 ANSWERS REGISTRY COPYRIGHT 2018 ACS on STN
 IN Benzeneacetic acid, α -methoxy- α -(trifluoromethyl)-,
 (α R)-, compd. with (3aR)-(3aR)-2,3,3a,4,5,6-hexahydro-8-methyl-1H-
 pyrazino[3,2,1-jk]carbazole (1:1)
 CM 1

Absolute stereochemistry.



CM 2

Absolute stereochemistry. Rotation (+).




For a complete list of valid display formats and field codes, enter
HELP FORMAT or HELP DFIELDs at an arrow prompt (=>).

If you need further assistance, contact your local Help Desk.


TYPE "END" TO RETURN TO AN ARROW PROMPT OR

L3 34 ANSWERS REGISTRY COPYRIGHT 2018 ACS on STN
IN 1H-Pyrazino[3,2,1-jk]carbazole, 2,3,3a,4,5,6-hexahydro-8-methyl-, (3aS)-,
methanesulfonate (1:1)
CM 1

Absolute stereochemistry.




CM 2




L3 34 ANSWERS REGISTRY COPYRIGHT 2018 ACS on STN
IN 1H-Pyrazino[3,2,1-jk]carbazole, 2,3,3a,4,5,6-hexahydro-8-methyl-, (3aR)-,
2-hydroxy-1,2,3-propanetricarboxylate (1:1)
CM 1

Absolute stereochemistry.




CM 2




L3 34 ANSWERS REGISTRY COPYRIGHT 2018 ACS on STN
 IN Benzeneacetic acid, α -hydroxy-, (α S)-, compd. with
 (3aR)-2,3,3a,4,5,6-hexahydro-8-methyl-1H-pyrazino[3,2,1-jk]carbazole (1:1)
 CM 1

Absolute stereochemistry.




CM 2

Absolute stereochemistry. Rotation (+).



L3 34 ANSWERS REGISTRY COPYRIGHT 2018 ACS on STN
 IN 1H-Pyrazino[3,2,1-jk]carbazole, 2,3,3a,4,5,6-hexahydro-8-methyl-, (-)-


Rotation (-).




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 34 ANSWERS REGISTRY COPYRIGHT 2018 ACS on STN
 IN Carbonic acid, dilithium salt, mixt. with
 2,3,3a,4,5,6-hexahydro-8-methyl-1H-pyrazino[3,2,1-jk]carbazole (9CI)

CM 1




CM 2




• 2 Li

L3 34 ANSWERS REGISTRY COPYRIGHT 2018 ACS on STN
IN Propanoic acid, 2-hydroxy-, compd. with
2,3,3a,4,5,6-hexahydro-8-methyl-1H-pyrazino[3,2,1-jk]carbazole (1:1)
CM 1




CM 2



L3 34 ANSWERS REGISTRY COPYRIGHT 2018 ACS on STN
IN 1H-Pyrazino[3,2,1-jk]carbazole, 2,3,3a,4,5,6-hexahydro-8-methyl-,
monohydrochloride, (R)- (9CI)


Absolute stereochemistry.



• HCl


L3 34 ANSWERS REGISTRY COPYRIGHT 2018 ACS on STN
IN 1H-Pyrazino[3,2,1-jk]carbazole, 2,3,3a,4,5,6-hexahydro-8-methyl-,

conjugate acid (1:1)




• H⁺

L3 34 ANSWERS REGISTRY COPYRIGHT 2018 ACS on STN
IN 1H-Pyrazino[3,2,1-jk]carbazole, 2,3,3a,4,5,6-hexahydro-3-d-8-methyl- (9CI)



L3 34 ANSWERS REGISTRY COPYRIGHT 2018 ACS on STN
IN 1H-Pyrazino[3,2,1-jk]carbazole, 2,3,3a,4,5,6-hexahydro-8-methyl-,
hydrochloride (1:?)



• x HCl

L5 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2018 ACS on STN
TI Novel psychotropic medicinal composition
AN 1974:100209 CAPLUS [Full-text](#)
DT Patent
LA English
IN Mashkovskii, M. D.; Grinev, A. N.; Shvedov, V. I.; Andreeva, N. I.;
Altukhova, L. B.
PA Ordzhonikidze, S., All-Union Scientific-Research Chemical-Pharmaceutical
Institute
DN 80:100209
FAN.CNT 1
SO Brit., 2 pp.
CODEN: BRXXAA

PI


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
	GB 1340528	A	19731212	GB 1971-8008	19710327
PRAI	GB 1971-8008	A	19710327		
AB	Antidepressant tablets wt. 0.1-0.2 g for oral administration contained 0.025-0.05 g particulate 1,10-trimethylene-8-methyl-1,2,3,4,-				

tetrahydropyrazino[1,2-a]indole hydrochloride(I) and a particulate carrier of **lactose**, sugar, or starch.

GI For diagram(s), see printed CA through Vol 151.

IT **16154-78-2**

RL: BIOL (Biological study)
(antidepressant and psychotropic compns.)



• HCl

RN 16154-78-2 CAPLUS

CN 1H-Pyrazino[3,2,1-jk]carbazole, 2,3,3a,4,5,6-hexahydro-8-methyl-, hydrochloride (1:1) (CA INDEX NAME)

L5 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2018 ACS on STN

[PatentPak PDF](#)

TI Pharmaceutical compositions comprising an agent with serotonin receptor modulating activity for sleep disorders

AN 2006:631165 CAPLUS [Full-text](#)

DT Patent

LA English

IN Rariy, Roman V.; Heffernan, Michael

PA Collegium Pharmaceutical, Inc., USA

DN 145:110313

FAN.CNT 1

SO PCT Int. Appl., 57 pp.

CODEN: PIXXD2

PPPI

PATENT NO.	KIND	DATE	LANGUAGE	PatentPak
WO 2006069030	A1	20060629	English	PDF
AU 2005319367	A1	20060629	English	PDF
AU 2005319367	B2	20120524	English	PDF
EP 1833467	B1	20160803	English	PDF
US 8512751	B2	20130820	English	PDF
US 20130337061	A1	20131219	English	PDF
US 20150098994	A1	20150409	English	PDF

PI

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006069030	A1	20060629	WO 2005-US46049	20051220
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,			

KG, KZ, MD, RU, TJ, TM


AU 2005319367	A1	20060629	AU 2005-319367	20051220
AU 2005319367	B2	20120524		
CA 2590802	A1	20060629	CA 2005-2590802	20051220
EP 1833467	A1	20070919	EP 2005-854713	20051220
EP 1833467	B1	20160803		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,				
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2008524332	T	20080710	JP 2007-548372	20051220
US 20080200508	A1	20080821	US 2007-793392	20070619
US 8512751	B2	20130820		
CN 101132777	A	20080227	CN 2005-80043729	20070620
IN 2007DN04915	A	20070817	IN 2007-DN4915	20070626
KR 2007087678	A	20070828	KR 2007-7016730	20070720
US 20130337061	A1	20131219	US 2013-13970350	20130819
US 20150098994	A1	20150409	US 2014-14306637	20140617
PRAI US 2004-60637655	P	20041220		
WO 2005-US46049	W	20051220		
US 2007-793392	A3	20070619		
US 2013-13970350	B1	20130819		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Pharmaceutical compns. are provided for the pharmacol. treatment of breathing disorders and, more specifically, to compns. contg. agents having serotonin receptor modulating activity for the alleviation of sleep apnea (central and obstructive) and other sleep-related breathing disorders wherein the active ingredients are released such as to extend effective blood plasma concns. across the period of sleep. For example, ondansetron immediate release tablets were prepd. contg. ondansetron HCl dihydrate 9.98 mg, **lactose** 29.14 mg, Prosolv 50 29.14 mg, Ac-Di-Sol 3.75 mg, SDS 1.5 mg, Aerosil 0.75 mg, and Mg stearate 0.75 mg. Ondansetron immediate release tablets were then coated with Eudragit L100/S100 blend to obtain delayed release tablets.

IT **60762-57-4**, Pirlindole

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral compns. comprising serotonin receptor modulator for treatment of sleep disorders)



RN 60762-57-4 CAPLUS

CN 1H-Pyrazino[3,2,1-jk]carbazole, 2,3,3a,4,5,6-hexahydro-8-methyl- (CA INDEX NAME)

L5 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2018 ACS on STN

[PatentPak PDF](#)

TI Pharmaceutical solid form formulations eliciting antidepressant effect and method for their preparation

AN 2004:239743 CAPLUS [Full-text](#)

DT Patent

LA Russian

IN Bugaitsev, A. A.

PA Ukraine

DN 140:380628

FAN.CNT 1

SO Russ., No pp. given
CODEN: RUXXE7

PPPI

PATENT NO.	KIND	DATE	LANGUAGE	PatentPak
RU 2223752	C1	20040220	Russian	PDF

PI


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RU 2223752	C1	20040220	RU 2002-122482	20020819

PRAI UA 2002-42656 A 20020403

AB The invention relates to pharmaceutical compns. eliciting antidepressant effect and method for their prepn. Pharmaceutical compns. comprise an indole deriv. and excipients. As an indole deriv. pharmaceutical compn. comprises pyrazidol or incazan, or tetrindole. The excipients include starch, cellulose or its deriv.; stearic acid, stearates; sugar, **lactose** or its deriv. in definite ratios. Pharmaceutical compn. represents solid medicinal form. The claimed method for prepg. pharmaceutical compn. provides maximal yield and drug stability.

IT **16154-78-2**, Pyrazidol

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical solid form formulations eliciting antidepressant effect and method for their prepn.)



• HCl

RN 16154-78-2 CAPLUS

CN 1H-Pyrazino[3,2,1-jk]carbazole, 2,3,3a,4,5,6-hexahydro-8-methyl-, hydrochloride (1:1) (CA INDEX NAME)

L5 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2018 ACS on STN

[PatentPak PDF](#) | [PatentPak PDF+](#) | [PatentPak Interactive](#)

TI Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors

AN 2003:492667 CAPLUS [Full-text](#)

DT Patent

LA English

IN Davis, Harry R.; Ress, Rudyard J.; Strony, John T.; Veltri, Enrico P.

PA Schering Corporation, USA

DN 139:57965

FAN.CNT 12

SO U.S. Pat. Appl. Publ., 40 pp., Cont.-in-part of U.S. Ser. No. 166,942.
CODEN: USXXCO

PPPI

PATENT NO.	KIND	DATE	LANGUAGE	PatentPak
US 20030119428	A1	20030626	English	PDF PDF+ Interactive
US 20030105028	A1	20030605	English	PDF PDF+ Interactive
AU 2007201970	A1	20070524	English	PDF
AU 2007201970	B2	20080417	English	PDF
AU 2008201609	A1	20080501	English	PDF


PI

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	US 20030119428	A1	20030626	US 2002-247397	20020919
	US 7053080	B2	20060530		
	US 20030105028	A1	20030605	US 2002-166942	20020611
	US 6982251	B2	20060103		
	US 20060009399	A1	20060112	US 2005-216515	20050831
	AU 2007201970	A1	20070524	AU 2007-201970	20070503
	AU 2007201970	B2	20080417		
	AU 2008201609	A1	20080501	AU 2008-201609	20080410
	AU 2008201609	B2	20081211		
PRAI	US 2001-60323840	P	20010921		
	US 2002-166942	A2	20020611		
	US 2000-60256875	P	20001220		
	US 2001-23295	A2	20011217		
	US 2002-247397	A3	20020919		
	AU 2006-202618	A3	20060620		
	AU 2007-201970	A3	20070503		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


AB The present invention provides methods for the treatment of obesity using sterol or 5 α -stanol absorption inhibitors and compns. and therapeutic combinations including sterol or 5 α -stanol absorption inhibitors and at least one obesity control medication. Prepn. of azetidinone derivs. is described. A tablet contained active compd. 102, **lactose** monohydrate 553, microcryst. cellulose 204, povidone (K29-32) 45, croscarmellose sodium 86, sodium lauryl sulfate 27, and magnesium stearate 1 mg.

GI



IT **60762-57-4**, Pirlindole

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and therapeutic combinations for treatment of obesity using sterol absorption inhibitors)



RN 60762-57-4 CAPLUS

CN 1H-Pyrazino[3,2,1-jk]carbazole, 2,3,3a,4,5,6-hexahydro-8-methyl- (CA INDEX NAME)

L5 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2018 ACS on STN

[PatentPak PDF](#) | [PatentPak PDF+](#) | [PatentPak Interactive](#)

TI Use of monoamine oxidase inhibitors for the manufacture of drugs intended

for the treatment of obesity
 AN 2001:137010 CAPLUS [Full-text](#)
 DT Patent
 LA English
 IN Rosenzweig, Pierre
 PA Sanofi-Synthelabo, Fr.
 DN 134:198077
 FAN.CNT 1
 SO PCT Int. Appl., 11 pp.
 CODEN: PIXXD2

PPPI

PATENT NO.	KIND	DATE	LANGUAGE	PatentPak
WO 2001012176	A2	20010222	English	PDF PDF+ Interactive

PI


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001012176	A2	20010222	WO 2000-EP7917	20000808
WO 2001012176	A3	20020321		
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW:				
GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1078632	A1	20010228	EP 1999-116026	19990816
R:				
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2377133	A1	20010222	CA 2000-2377133	20000808
AU 2000064419	A	20010313	AU 2000-64419	20000808
BR 2000013282	A	20020423	BR 2000-13282	20000808
EP 1210080	A2	20020605	EP 2000-951508	20000808
R:				
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
TR 2002000376	T2	20020621	TR 2002-376	20000808
JP 2003506485	T	20030218	JP 2001-516522	20000808
HU 2002003601	A2	20030228	HU 2002-3601	20000808
EE 2002000062	A	20030415	EE 2002-62	20000808
ZA 2002000738	A	20030128	ZA 2002-738	20020128
IN 2002MN00175	A	20060113	IN 2002-MN175	20020211
NO 2002000770	A	20020416	NO 2002-770	20020215
MX 2002001649	A	20021023	MX 2002-1649	20020215
PRAI EP 1999-116026	A	19990816		
WO 2000-EP7917	W	20000808		

AB The present invention relates to the use of reversible selective inhibitors of monoamine oxidase A (MAO-A), reversible selective inhibitors of monoamine oxidase B (MAO-B) or reversible mixed inhibitors of MAO-A and MAO-B in the manuf. of drugs intended for the treatment of obesity. In obese rats, a 5-wk chronic treatment with befloxatone induced a dose related redn. of body wt. gain. This effect was significant from the first week of treatment of treatment for the dose of 10 mg/kg/day. An oral formulation of befloxatone was prepd. by granulating befloxatone 2.5 mg, starch 5 mg, **lactose** monohydrate 83 mg, Povidone K29/32 5 mg, Crospovidone 4 mg, and Mg stearate 0.5% and filling the granules obtained into gelatin capsules.

IT **60762-57-4**, Pirlindole

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(compns. of monoamine oxidase inhibitors for treatment of obesity)



RN 60762-57-4 CAPLUS

CN 1H-Pyrazino[3,2,1-jk]carbazole, 2,3,3a,4,5,6-hexahydro-8-methyl- (CA INDEX NAME)

L5 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2018 ACS on STN

[PatentPak PDF](#)

TI Pharmaceutical compositions containing nicotine or a ligand of nicotine receptors and a monamine oxidase inhibitor and their use for treating tobacco withdrawal symptoms

AN 2000:553442 CAPLUS [Full-text](#)

DT Patent

LA French

IN Caille, Dominique; George, Pascal; Jegham, Samir; Robineau, Pascale; Scatton, Bernard; Zivkovic, Branimir

PA Sanofi-Synthelabo, Fr.

DN 133:168383

FAN.CNT 1

SO PCT Int. Appl., 37 pp.

CODEN: PIXXD2

PPPI

PATENT NO.	KIND	DATE	LANGUAGE	PatentPak
WO 2000045846	A1	20000810	French	PDF

PI


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000045846	A1	20000810	WO 2000-FR193	20000128
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2788982	A1	20000804	FR 1999-1144	19990202
FR 2788982	B1	20020802		
CA 2361437	A1	20000810	CA 2000-2361437	20000128
AU 2000022988	A	20000825	AU 2000-22988	20000128
EP 1150715	A1	20011107	EP 2000-901660	20000128
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
HU 2002001279	A2	20020928	HU 2002-1279	20000128
JP 2002536342	T	20021029	JP 2000-596965	20000128
MX 2001007812	A	20020108	MX 2001-7812	20010802
PRAI FR 1999-1144	A	19990202		
WO 2000-FR193	W	20000128		

AB The invention concerns novel pharmaceutical compns. contg. nicotine or a ligand of nicotine receptors and a monamine oxidase inhibitor designed for treating tobacco withdrawal symptoms. A bilayer tablet contained befloxatone 5, **lactose** 66, microcryst. cellulose 20, povidone 4, crospovidone 4, and magnesium stearate 1% in the first layer, and nicotine polarcrilex 5, microcryst. cellulose 20 povidone 4, hydroxypropyl Me cellulose 25, magnesium stearate 1, and **lactose** q.s. 100% in the second layer.

IT **60762-57-4**, Pirlindole

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical compns. contg. nicotine or ligand of nicotine receptors and monamine oxidase inhibitor and their use for treating tobacco withdrawal symptoms)



RN 60762-57-4 CAPLUS

CN 1H-Pyrazino[3,2,1-jk]carbazole, 2,3,3a,4,5,6-hexahydro-8-methyl- (CA INDEX NAME)

L5 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2018 ACS on STN

TI Novel psychotropic medicinal composition

AN 1974:100209 CAPLUS [Full-text](#)

DT Patent

LA English

IN Mashkovskii, M. D.; Grinev, A. N.; Shvedov, V. I.; Andreeva, N. I.; Altukhova, L. B.

PA Ordzhonikidze, S., All-Union Scientific-Research Chemical-Pharmaceutical Institute

DN 80:100209

FAN.CNT 1

SO Brit., 2 pp.

CODEN: BRXXAA

PI

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
GB 1340528	A	19731212	GB 1971-8008	19710327
PRAI GB 1971-8008	A	19710327		


AB Antidepressant tablets wt. 0.1-0.2 g for oral administration contained 0.025-0.05 g particulate 1,10-trimethylene-8-methyl-1,2,3,4,-tetrahydropyrazino[1,2-a]indole hydrochloride(I) and a particulate carrier of **lactose**, sugar, or starch.

GI For diagram(s), see printed CA through Vol 151.

IT **16154-78-2**

RL: BIOL (Biological study)

(antidepressant and psychotropic compns.)



• HCl

RN 16154-78-2 CAPLUS

CN 1H-Pyrazino[3,2,1-jk]carbazole, 2,3,3a,4,5,6-hexahydro-8-methyl-,
hydrochloride (1:1) (CA INDEX NAME)